AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01498081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via inhalation
Study NCT01498081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indacaterol
Description: Indacaterol administered via inhalation
Study NCT01498081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indacaterol + Tiotropium
Description: Indacaterol + Tiotropium administered inhalation
Study NCT01070524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5188 pMDI
Description: CHF 5188: fixed combination budesonide/carmoterol
Study NCT01070524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide extrafine pMDI
Description: Budesonide extrafine pMDI
Study NCT01070524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide(r) Evohaler(r)
Description: Seretide(r) Evohaler(r): fixed combination fluticasone/salmeterol
Study NCT03046940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-centered style of communication
Description: Different doctor-patient communication
Study NCT03046940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doctor-centered style of communication
Description: Different doctor-patient communication
Study NCT02136784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sublingual tablet placebo
Description: Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
Study NCT03973957 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Indwelling pleural catheter placement
Description: Indwelling pleural catheter placement by interventional pulmonologist
Study NCT03973957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: Administration of intravenous fentanyl prior to talc slurry instillation in order to avoid pain associated with talc slurry application
Study NCT03973957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talc Slurry
Description: Administration of 5 grams of medical grade sterile talc mixed in 50 milliliters of normal saline solution via indwelling pleural catheter for purposes of talc slurry pleurodesis
Study NCT03973957 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drainage collection bag
Description: Attachment of one-way Heimlich valve with drainage collection bag circuit to indwelling pleural catheter after talc slurry application for purposes of drainage and pleurodesis in the outpatient setting rather than the inpatient setting.
Study NCT00706992 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given subcutaneously
Study NCT01289951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir 400 mg/12hours
Study NCT01289951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg/12hours
Study NCT03560921 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: urinary NGAL
Description: measurement urinary NGAL using the ARCHITECT technique
Study NCT02713815 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: Stimulate the dorsomedial prefrontal cortex for 4 weeks by Theta-burst stimulation (TBS), once a day
Study NCT02713815 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: sham repetitive transcranial magnetic stimulation (rTMS)
Description: Stimulate the dorsomedial prefrontal cortex for 4 weeks by sham Theta-burst stimulation (TBS), once a day
Study NCT00678626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871
Description: Docetaxel administered every 3 weeks. CP-751,871 administered every 3 weeks. CP-751,871 administration (20 mg/kg IV) will continue after the docetaxel is stopped.
Study NCT00678626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel only is administered every 3 weeks. After progression, administration with CP-751, 871 (20 mg/kg IV) is permitted.
Study NCT00903552 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza VLP Vaccine
Study NCT00903552 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: phosphate-buffered saline (PBS)
Study NCT03046719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0,5%
Description: Bupivacaine 0,5% was given on the subconjunctiva, in between stitches by the surgeon after finishing the last stitches
Study NCT03046719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0,9%
Description: NaCl 0,9% was given on the subconjunctiva, in between stitches by the surgeon after finishing the last stitches
Study NCT00283413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Covered Stent System
Description: Self-expanding, polytetrafluoroethylene(PTFE)-covered, stent system
Study NCT00283413 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare metal stent
Description: Any commercially available bare metal stent for coronary indication
Study NCT02463799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223
Description: 6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223
Study NCT02463799 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sipuleucel-T
Description: 3 infusions of sipuleucel-T alone
Study NCT02463799 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Description: 3 infusions of sipuleucel-T alone
Study NCT04109859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: When using saline, if found mean arterial pressure \<65mmHg, Cardic Output>4L/min, Sequential Vascular Response\<800 (dyne×sec)/cm, starting dose of norepinephrine 0.04ug/min/kg
Study NCT04109859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Patients in the methylene blue group were given methylene blue before anesthesia and continued intraoperative pumping
Study NCT02477241 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Uroflowmetry
Description: A cystometric test measures how much urine the bladder can hold, how much pressure builds up inside the bladder as it stores urine, and how full it is when the urge to urinate begins. Uroflowmetry is the measurement of urine speed and volume.
Study NCT02477241 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: fMRI
Description: Functional magnetic resonance imaging or functional MRI (fMRI) is a functional neuroimaging procedure using MRI technology that measures brain activity by detecting associated changes in blood flow. This technique relies on the fact that cerebral blood flow and neuronal activation are coupled. When an area of the brain is in use, blood flow to that region also increases.
Study NCT02459418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afolia
Description: During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.~Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27
Study NCT02459418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Afolia
Description: During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.~Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27
Study NCT02459418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: US Gonal-f®
Description: During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.~Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27
Study NCT02459418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US Gonal-f®
Description: During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.~Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27
Study NCT03436342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-Pentixafor
Description: Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga-Pentixafor will be used to image lesions of MM and lymphoma by PET/CT.
Study NCT03470142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional laparoscopy-assisted surgery
Description: All surgical procedures will be performed by the surgery team ,which is leaded by professor Sun Dong-Hui and Wang Quan. The traditional laparoscopic operation undergo and then a small incision(5cm) is made in the middle of the lower abdominal wall to trim the mesangial membrane and remove the specimen. At last the anastomosis operation undergo by the laparoscopic operation.
Study NCT03470142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total laparoscopic surgery with no incision (natural orifice transluminal endoscopic surgery, NOSES)
Description: All surgical procedures will be performed by the surgery team ,which is leaded by professor Sun Dong-Hui and Wang Quan. The whole procedures undergo by total laparoscopic surgery with no incision in the abdominal wall. The specimen then will be removed through natural orifice (anal).
Study NCT00477776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide (Maxolon)
Description: Metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, once a day for day 11 and 12
Study NCT03347513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triple attack therapy
Description: eradication of H-pylori using triple attack therapy.
Study NCT03347513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous(II)-glycine-sulphate complex 567.7 mg capsules
Description: Iron therapy will be given to both groups twice daily for one month.
Study NCT03347513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous(II)-glycine-sulphate complex 567.7 mg capsules
Description: Iron therapy will be given to both groups twice daily for one month.
Study NCT01995721 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4-valent HPV vaccine
Description: Vaccination with 4-valent HPV vaccine in months 0., 2., 6.
Study NCT02778503 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Cost
Description: Surfaces allocated to this group will be treated with a high-cost glass ionomer cement restoration (Fuji IX, GC America, USA), according to the manufacturer's instructions.
Study NCT02778503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Cost
Description: Surfaces allocated to this group will be treated with a low-cost glass ionomer cement restoration (Maxxion R, FGM, BRA), according to the manufacturer's instructions.
Study NCT03532633 — intervention group
Intervention type: PROCEDURE
Intervention: cord blood
Description: collection of cord blood
Study NCT03532633 — intervention group
Intervention type: PROCEDURE
Intervention: blood sample infant
Description: collection of remnant of clinically indicated blood sample
Study NCT03532633 — intervention group
Intervention type: PROCEDURE
Intervention: blood sample mother
Description: collection of remnant of clinically indicated blood sample. If not available blood sample is taken after mother agreed
Study NCT03532633 — intervention group
Intervention type: PROCEDURE
Intervention: breast milk
Description: collection of breast milk 1/week during neonatal care (maximum 8 weaks)
Study NCT00477776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10, once a day from day 11 to 12
Study NCT00886951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I123MNI388/I123MNI390
Description: Subjects will be dosed by intravenous injection up to 5 mCi and not to exceed 5.5 (not >10% of 5 mCi limit) 123-I MNI-388 or 123-I MNI-390.
Study NCT03144583 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adult differentiated autologous T-cells
Description: After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-CD19 specificity will be transfused.
Study NCT03842488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: RAL QD
Description: Prescription of 2x RAL 600mg (1200MG) once daily
Study NCT03842488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: DRV/cb
Description: Prescription of DARUNAVIR/COBICISTAT 800 Mg-150 Mg once daily
Study NCT02860910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy
Study NCT00767013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DSCT, TTE
Description: One assessment each
Study NCT01518478 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluzone® Intradermal (Sanofi Pasteur Inc.)
Description: Fluzone® Intradermal trivalent vaccine is a clear-to-slightly opalescent, preservative-free suspension containing formaldehyde-inactivated split influenza viruses for intradermal delivery of 0.1 mL via an ultra-fine micro-needle. The vaccine is supplied as a single-dose, in a latex-free, pre-filled microinjection system. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs.~Fluzone® Intradermal is standardized according to United States Public Health Service (US PHS) requirements and is formulated to contain HA of each of the following three influenza strains recommended for the 2011-2012 influenza season: A/California/07/2009 X-179A (H1N1)-like virus, A/Perth/16/2009 (H3N2)-like virus, and B/Brisbane/60/2008-like virus.
Study NCT02969863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bihormonal Bionic Pancreas
Description: Participants will wear a Bionic Pancreas that uses glucagon and insulin (bihormonal) to automate their glucose control based on continuous glucose monitor readings.
Study NCT02969863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin Only Bionic Pancreas
Description: Participants will wear a Bionic Pancreas that uses just insulin (insulin-only) to automate their glucose control based on continuous glucose monitor readings.
Study NCT04512469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low molecular weight mesh
Description: Following liver implantation, the subcostal incision will be closed using a running fascial closure with absorbable 1-0 Polydioxanone (PDS) suture and staples, with the treatment group also receiving a mesh.
Study NCT01945333 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive remediation
Description: Cognitive remediation sessions include working on computer based cognitive exercises and participating in a verbal discussion.
Study NCT05044260 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct sinus lift with titanium reinforced PTFE membrane
Description: Implants will be placed immediately after sinus lifting procedure and maintaining the sinus membrane in position using PTFE titanium reinforced membrane.
Study NCT02875847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMO1
Study NCT02875847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMO2
Study NCT02875847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dextropur
Study NCT02199301 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplantation Conditioning for BMT
Description: Transplantation Conditioning for BMT (POD#-7\~-1) POD#-7: Rituximab (Mabthera, Roche Pharma Aktiengesellschaft (AG) Swiss) 375/m2 iv infusion POD#-6\~-3: Fludarabine (Fludara Inj., Bayer AG, Germany) 30mg/m2/day iv infusion POD#-5\~-4: Cyclophosphamide (Endoxan Inj., Baxter Oncology Gesellschaft mit beschränkter Haftung (GmbH), Germany) 30mg/kg/day iv infusion POD#-2: (Rituximab 375/m2 iv infusion) POD#-1: Thymic irradiation (Dose, 700cGy)
Study NCT03509272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote monitoring
Description: Intervention Description: Patients can participate in the study when they're 10 weeks pregnant. At 10 weeks: a NICCOMO, Maternal Venous Doppler Echography and Maltron measurement will be taken. This measurement will be repeated at 20 weeks of pregnancy, and 30 weeks of pregnancy when they're aberrant.~When the measurements are abnormal, the patients will be included in the remote monitoring study. The following protocol and devices will be applied:~Device What When Withings Wireless Blood Pressure Monitor Blood Pressure 2x/day Withings Pulse O² Activity Day and night Withings Smart Body Analyzer Weight~1x/day
Study NCT03414762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO Negative Pressure Wound Therapy
Description: The PICO unit is a single patient use, battery-powered, disposable unit that can provide continuous 80 - 125 mmHg negative pressure over a 5 to 7-day therapy period.The dressing is applied to the wound and extra strips are placed over the outside edge to help hold the dressing in place. When the pump is turned on, air is pulled out of the dressing and excess fluid from the wound will start to enter the dressing.
Study NCT03414762 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dressing
Description: The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing
Study NCT03368131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: intravenously administered with the loading dose of 8 mg/kg followed by maintenance dose of 6mg/kg in day 1 of each cycle
Study NCT03368131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825\~1000mg/m2 bid d1-14
Study NCT03368131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 825\~1000mg/m2 bid d1-14
Study NCT03368131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2 Ivgtt d1 q3w
Study NCT02969863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitored for Hypoglycemia
Description: During half of the study arms (one each bihormonal bionic pancreas, insulin-only bionic pancreas and usual care) the subjects will be remotely monitored for device connectivity and hypoglycemia, and will be notified by study staff any time their continuous glucose monitor reads less than 50 mg/dl for 15 mintues.
Study NCT02969863 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monitored for Hypoglycemia
Description: During half of the study arms (one each bihormonal bionic pancreas, insulin-only bionic pancreas and usual care) the subjects will be remotely monitored for device connectivity and hypoglycemia, and will be notified by study staff any time their continuous glucose monitor reads less than 50 mg/dl for 15 mintues.
Study NCT02969863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Not Monitored for Hypoglycemia
Description: During half of the study arms (one each bihormonal bionic pancreas, insulin-only bionic pancreas and usual care) the subjects will be remotely monitored for device connectivity only, not hypoglycemia.
Study NCT03368131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130 mg/m2 Ivgtt d1 q3w
Study NCT03368131 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 45 Gray (unit) Gy/25f （1.8Gy/f/d，5 f/w）
Study NCT03368131 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 45 Gray (unit) Gy/25f （1.8Gy/f/d，5 f/w）
Study NCT02338791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Mobilization
Description: Stabilization of the glenoid fossa with movement of the humerus using varying degrees of force as applied by a physical therapist. Subject is positioned with the shoulder in 55 degrees of abduction and 30 degrees of horizontal adduction. Manual force is applied by a physical therapist on the proximal humeral head moving the humeral head posterior, inferior or lateral (distraction). An ultrasound transducer placed over the anterior shoulder joint provides imaging of the humeral head and the glenoid fossa. This manual intervention is repeated three times in each direction on each arm.
Study NCT03570034 — intervention group
Intervention type: DEVICE
Intervention: Obalon Balloon System
Description: Obalon Balloon System with a moderate intensity Weight Loss Behavioral Modification Program